title: Rapid and sustained resolution of serous retinal detachment in Sturge-Weber syndrome after single injection of intravitreal bevacizumab.
abstract: OBJECTIVE
  To report the effect of a single intravitreal bevacizumab injection on serous retinal detachment (SRD) in Sturge-Weber syndrome (SWS).
  
  
  METHODS
  Interventional case report.
  
  
  METHODS
  A 15-year-old boy with history of SWS was referred with a complaint of sudden visual loss 2 days before, having choroidal hemangioma accompanied with SRD. Visual acuity was 20/160.
  
  
  RESULTS
  He was treated with 1.25 mg of bevacizumab injected intravitreally. One week later, the retina was completely attached and visual acuity was 20/20. After 20 months, without repeating the injection, the retina remained attached and vision was stable.
  
  
  CONCLUSIONS
  An early single dose of intravitreal bevacizumab is effective in the treatment of serous retinal detachment in SWS with good long-term results.
authors.affiliation: Eye Research Center, School of Medicine, Mashhad University Of Medical Sciences, Mashhad, Iran. shoeibin@mums.ac.ir
authors.forename: Nasser
authors.initials: N
authors.lastname: Shoeibi
authors.forename: Hamid
authors.initials: H
authors.lastname: Ahmadieh
authors.forename: Mojtaba
authors.initials: M
authors.lastname: Abrishami
authors.forename: Hoorak
authors.initials: H
authors.lastname: Poorzand
mesh_terms: D000293:Adolescent; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D012163:Retinal Detachment / Q000188:drug therapy*; D012720:Severity of Illness Index; D013341:Sturge-Weber Syndrome / Q000188:drug therapy*; D016896:Treatment Outcome; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab